



# Virtual Stakeholder Workshop of the CCQM-PAWG Task group on Protein Structure and Activity Measurements

## **Protein structure and activity**

17-20 February 2025

## **Agenda**

#### Feb 17<sup>th</sup> 13:00 to 15:30 UTC+1

Welcome: Robert Wielgosz, BIPM Background: Max Ryadnov, NPL, UK

| Session 1: Progress, Challenges and Opportunities   |  |
|---|--|
|   | Chair, Max Ryadnov, NPL, UK                |
| Integration of structural biology with drug discovery: quantitative challenges for protein description and characterisation | Phil Kerry,<br>Evotec, DE                  |
| Generating living datasets and public benchmarking opportunities for sequence-to-function prediction models                 | Dana Cortade<br>AlignBio, US               |
| Advanced atomic force microscopy for the characterisation of proteins and protein assemblies                                | Christian Bippes<br>NanoSurf, CH           |
| Understanding synergistic antimicrobial peptide combinations through computation  | Chris Lorenz,<br>King's College London, UK |
| Challenges in quality control for biological reagents   | Yuning Chen,<br>Sino Biological Inc., CN   |
| Chair led Q&A   | •  |

### Feb 18th 13:00 to 15:30 UTC+1

Welcome Day 2: Amandine Boeuf, LNE, France Chair Feedback Session 1: Max Ryadnov, NPL, UK

| Session 2: Protein structure measurements  |   |
|--|---|
| Chair, A   | mandine Boeuf, LNE, France  |
| Collagen Type 0 – development of a next generation collagen for medicine                                       | Andrew Mearns-Spragg,<br>Jellagen, UK   |
| Cross-linking probes for structural analysis of Tau and phospho-Tau proteins                                   | Cristian Arsene,<br>PTB, DE   |
| Higher-order structure measurement of biotherapeutics by NMR   | John Marino,<br>NIST, US  |
| Mapping protein structure and dynamics using mass spectrometry approaches: a nanobody characterisation example | Luise Luckau<br>NML@LGC, UK   |
| Glycomics and glycoproteomics characterization of protein standards by mass spectrometry                       | Renee Ruhaak, Elena<br>Dominguez-Vega,<br>Leiden University Medical<br>Center, NL |
| Chair led Q&A  |   |

## Feb 19<sup>th</sup> 13:00 to 15:30 UTC+1

Welcome Day 3

Chair Feedback Session 2: Amandine Boeuf, LNE, France

| Session 3: Protein activity measurements   |  |
|--|--|
| Chair, (   | Claudia Swart, PTB, Germany                |
| Interrogating the binding spectrum of INFEX-702: a novel therapeutic antibody targeting <i>P. aeruginosa</i>         | Victoria Savage,<br>Infex Therapeutics, UK |
| Research on protein immuno-affinity concentration and enzyme catalytic concentration measurement                     | Liqing Wu,<br>NIM, CN                      |
| Structural flexibility of CyaA toxin is crucial from secretion to host cell hijacking                                | Alex Chenal<br>Institut Pasteur, FR        |
| Single-Cell Proteomics: Analytical Parameters, Metrics, and Applications   | Adriana Franco Paes Leme<br>LNBio, BR      |
| Characterization of therapeutic protein structures using native IMS-MS in combination with non-denaturing LC methods | Oscar Hernandez Alba,<br>LSMBO-CNRS, FR    |
| Chair led Q&A  |  |

## Feb 20<sup>th</sup> 13:00 to 15:30 UTC+1

Welcome Day 4

Chair Feedback Session 3: Claudia Swart, PTB, Germany

| Session 4: Standardization: now and future   |                               |
|--|-------------------------------|
|  | Chair, Liqing Wu, China       |
| Protein design for reference materials: structure to activity measurements                                 | James Noble<br>NPL, UK        |
| Training AI with standard VLPs: a novel strategy for rapid virus identification                            | Andrea Valsesia<br>EC JRC, IT |
| ProMET: Metrology frameworks for protein structure characterisation and better definition of the measurand | Amandine Boeuf<br>LNE, FR     |
| Correlating bioactivity to SI traceable units - present experience and future aspiration                   | Tim Rudd,<br>MHRA, UK         |
| Chair led Q&A  |                               |

Final remarks and Close: Max Ryadnov